Shares of Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Rating) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.75 and traded as low as $0.61. Northwest Biotherapeutics shares last traded at $0.64, with a volume of 7,043,841 shares changing hands.
Northwest Biotherapeutics Stock Performance
The stock has a market cap of $686.45 million, a price-to-earnings ratio of -6.35 and a beta of -0.03. The company has a 50-day moving average of $0.68 and a 200-day moving average of $0.75.
About Northwest Biotherapeutics
(Get Rating)
Northwest Biotherapeutics, Inc is a biotechnology company, which engages in the development of personalized immune therapies for cancer. It offers DCVax technology platform, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The company was founded by Alton L.
Featured Stories
- Get a free copy of the StockNews.com research report on Northwest Biotherapeutics (NWBO)
- On Holding AG Sprints Higher on Margin Expansion and Guidance
- Price Growth & Yield: For That Magical Combo, Leave the U.S.
- Game-Changing News For Tesla Investors
- DOW New Hghs Coming Sooner Than Later
- The Tide Is Turning For Harley-Davidson
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.